http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103263392-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 |
| filingDate | 2013-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103263392-B |
| titleOfInvention | A kind of Amoitone derivative long-circulation nanometer lipid carrier and preparation method thereof |
| abstract | The invention discloses a kind of Amoitone derivative long-circulation nanometer lipid carrier, main component is crude drug Amoitone B, polyglycol distearate, Solid lipid material, liquid fatty substance material, fat-soluble emulsifier, water soluble emulsifier and water for injection.Its preparation method is emulsifying evaporation-low temperature curing methods.Amoitone B long-circulating nanoliposome carrier prepared by the present invention has slow-release function in vivo, can the holdup time in the body of effective prolong drug, improves the bioavailability of medicine; There is comparatively high encapsulation rate and drug loading; Its particle diameter at about 200nm, can passive target in hepatic tissue, reduce the toxic and side effects of Amoitone B, and its good biocompatibility, easily to degrade, good stability, improves body toleration and patient compliance. |
| priorityDate | 2013-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.